Reuters logo
BRIEF-Nabriva posts results of leap 1 phase 3 trial in community acquired bacterial pneumonia
December 20, 2016 / 12:25 PM / a year ago

BRIEF-Nabriva posts results of leap 1 phase 3 trial in community acquired bacterial pneumonia

Dec 20 (Reuters) - Nabriva Therapeutics AG:

* Nabriva achieves 60% randomization target in leap 1 phase 3 trial in community acquired bacterial pneumonia

* Continue to anticipate topline clinical data from both CABP trials in second half of 2017

* Expects to complete enrollment of 550 patients by end of q2 of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below